Pa. Koivisto et I. Rantala, Amplification of the androgen receptor gene is associated with p53 mutation in hormone-refractory recurrent prostate cancer, J PATHOLOGY, 187(2), 1999, pp. 237-241
Citations number
34
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
p53 protein expression of 30 hormone-refractory locally recurrent prostate
cancers was compared with their matched untreated primary tumour specimens.
In addition, androgen receptor (AR) gene amplification and p53 protein imm
unostaining were compared. p53 positivity increased during hormonal therapy
from 17 per cent of the untreated primary tumours to 40 per cent of the ho
rmone-refractory recurrences (p=0.078). None of the p53-positive primary tu
mour specimens lost p53 positivity during hormonal therapy, Hormonere-fract
ory recurrences with AR gene amplification more frequently (p=0.0342) shelv
ed positive p53 immunostaining than tumours,without AR gene amplification,
75 and 27 percent, respectively. In summary, this study has shown that a ce
ll clone with P53 mutation seems to be selected for during endocrine therap
y and that positive p53 immunostaining correlates with AR gene amplificatio
n. These results suggest that inactivation of P53 may lead to genetic insta
bility in a subset of prostate carcinomas enabling them to achieve properti
es, such as AR gene amplification, that allow them to grow in low levels of
androgens and therefore cause tumour progression. Copyright (C) 1999 John
Wiley & Sons, Ltd.